BIRC5 and neoplasm: On the other hand, survivin is overexpressed in virtually every human tumor[15], making it difficult to identify discrete patient subset(s) likely to benefit from YM155-based therapy, and only limited information is available to rationally guide the incorporation of survivin antagonist(s) in effective combination regimens.